Our History

2012

   March: The company was officially established and registered with the Fujian Provincial Administration for Industry and Commerce.    

2013

  May: Officially relocated to and commenced operations at the new site in Jinshan Development Zone, Fuzhou.

2014

    November: The clinical trial application for the Class III chemical drug "Azilsartan Tablets" was officially submitted to the National Medical Products Administration (NMPA) for approval.

2015

     February: The clinical trial application for the Class III chemical drug "Sofosbuvir Tablets" was officially submitted to NMPA  for approval.

2016

    March: "Azilsartan Tablets" received the Clinical Trial Approval (CTA) from NMPA.

    May: "Sofosbuvir Tablets" received the Clinical Trial Approval (CTA) from NMPA.

    December: The company was nominated the "National High-Tech Enterprise".

2017

    March: The company was recognized as a “Fujian Science and Technology Enterprise”.

    June: The company was recognized as a"Fujian Provincial Innovative R&D Institution".

2020

     June :  "Mosapride Citrate Tablets" was approved for marketing by the NMPA (Approval Number: National Drug Approval No. H20203264).

     August: The company was granted the first Drug manufacturing License under the Marketing Authorization Holder (MAH) system by the Fujian Provincial Drug Administration.

     December: Class I chemical drug C019199 initiated its Phase I clinical trial at Beijing Cancer Hospital.

2021

    January: The "Haixi Pharma R&D and Transformation Center" was inaugurated by the Cangshan District People's Government.

    February: "Mosapride Citrate Tablets" participated in the 4th round of national centralized drug procurement and won the bid.

    March :  "Cinacalcet Hydrochloride Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213175).

                  "Escitalopram Oxalate Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213193).

    June: "Cinacalcet Hydrochloride Tablets" participated in the 5th round of national centralized drug procurement and won the bid.

    October: "Celecoxib Capsules" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213779).

    December: The company was once again recognized as a "National High-Tech Enterprise".

2022

    January:  "Amlodipine Atorvastatin Calcium Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20223037).

    April: "Valsartan and Amlodipine Tablets (I)" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20223239).

    June: " Valsartan Tablets" was approved for marketing by NMPA (drug approval number: National Drug Approval No. H20223427 (40mg)/H20223428 (80mg)).

    June: A wholly-owned subsidiary, "Haixi Pharmaceuticals (Fuzhou) Co., Ltd." was registered and established in Changle District..

    August: The company was awarded the “First Prize in the Growth Enterprise Category" at the 11th China Innovation and Entrepreneurship Competition (Fujian Division) and the 10th Fujian Innovation and Entrepreneurship Competition.

    November: With the approval of the Fujian Provincial Market Supervision and Administration Bureau, the company was officially renamed as "Fujian Haixi Pharmaceutical Co., Ltd."

2023

    March: "Amlodipine Atorvastatin Calcium Tablets" participated in the 8th round of national centralized drug procurement and won the bid.

    June: The groundbreaking ceremony was held for the  "Haixi Pharmaceutical Industrialization Base" construction project in Binhai New City, Changle District.

    October: Haixi designated as a "Fujian Provincial Drug Evaluation and Monitoring Center Training Base".

                   "Hydroxychloroquine Sulfate Tablets" weas approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20234411).

    November: "Nicergoline Tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20234574).

    December: Haixi was recognized as the "Most Promising Enterprise of Cangshan District".

2024

    April: "Rebamipide Tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20243604).

    June: "Diclofenac Sodium Enteric-coated Tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20244225).

    August: "Adenosine Cobalamin Capsules" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20244639).

    September: Nominated as a "National 'Little Giant' Enterprise".

    November: Recognized as the "2024 Fuzhou Enterprise Technology Center".

    December: “Bisoprolol Amlodipine Tablets” was approved for marketing by NMPA (Drug Approval Number: National Medical Products Administration Approval Letter H20249542).

                  "Hydroxychloroquine Sulfate Tablets" participated in the 10th  round of national centralized drug procurement and won the bid.December – Once again nominated as a “National High-Tech Enterprise.”

2025年    

     January: The official application for listing on the Main Board of the Hong Kong Stock Exchange was submitted.

     April: Class 1 chemical drug HX9428 Tablets obtained approval for clinical trials.

     June: The PhaseⅠclinical trial of HXP056, a Class 1 chemical drug project, was launched at Beijing Hospital.

               "Cetirizine Hydrochloride Oral Solution" received approval for marketing from the National Medical Products Administration (NMPA) (Drug Approval Number: National Drug Approval H20254566).

     July: "Benidipine Hydrochloride Tablets" obtained marketing approval from the National Medical Products Administration (NMPA) (Drug Approval Number: National Drug Approval H20255076).

     August: The Company successfully passed the listing hearing of The Stock Exchange of Hong Kong Limited.

     September: The Company obtained the Drug Production License (Category C), qualifying for independent pharmaceutical production.

     October: The Company was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Short Name: Haixi Pharma, Stock Code: 02637.HK).